COVIDRIVE expands its scope of studies and becomes id.DRIVE: new European partnership for burden and effectiveness studies on infectious diseases
id.DRIVE is a Public-Private-Partnership, which consists of a unique consortium of pharmaceutical companies, public health institutes and research groups who are joining forces to monitor infectious diseases and effectiveness of related pharmaceutical products in real-life in Europe. This is achieved by several pharmaceutical companies co-funding a research network of hospitals.
id.DRIVE leverages the COVID-19 vaccine effectiveness (VE) platform, COVIDRIVE (https://covidrive.eu/) (2021-2023) and Influenza VE platform, DRIVE (https://www.drive-eu.org/) (2017-2022). The partnership decided to make use of the established consortium and study network to expend its scope to all infectious diseases (IDs), lending its name to the new partnership. Next to vaccines, other pharmaceutical products such as antivirals and monoclonal antibodies will be studied.
While id.DRIVE will continue performing COVID-19 effectiveness studies, the consortium will initiate a first surveillance study starting mid-2024 on many other respiratory pathogens such as Influenza, RSV, Adenovirus, Human enterovirus, Parainfluenza virus, etc. This surveillance will help to understand the impact of these respiratory pathogens on serious illness, and to monitor the effectiveness of pharmaceutical products which are or will be available to prevent and cure these viral illnesses.
The id.DRIVE public-private partnership includes 8 partners, with AstraZeneca, Janssen, GSK, Novavax, Valneva and Pfizer being pharmaceutical company partners, P95 a Small and Medium Enterprise and Fisabio, a Spanish regional public health institute. The id.DRIVE study network covers 13 European countries and comprises 32 Study contributors, 5 primary care networks, and a nation-wide register. id.DRIVE is open for new partners to join the partnership and is expanding its study network.
To join us as id.DRIVE partner or study site, contact us at info@idDRIVE.org.
Find out more on www.iddrive.eu
P95 Attends Infectology Congress in Buenos Aires
P95 BV Attends Infectology Congress in Buenos Aires
Last week, P95 attended for the first time, the Congreso de Infectología 2023 organized by Asociación Panamericana de Infectología (API) and Sociedad Argentina de Infectología (SADI), which took place in Buenos Aires, Argentina.
This congress gathered renowned experts from the field of infectology, who shared lessons learnt and debated the most pressing and current topics on this topic.
More about the congress: https://www.congresosadi.com/
P95 Present at Bio Asia Pacific
P95 Present at Bio Asia Pacific
P95 is proud to be an official exhibitor at this year's Bio Asia Pacific in Bangkok. Bio Asia Pacific is one of the leading conferences and exhibitions for Biotechnology, Life Sciences and Smart Health in Southeast Asia. This year we had the opportunity to present a bit more about our company and our recently created Sout East Asia office in Bangkok by our Regional Director South East Asia, Tharinee Sakhakorn.
Extensive experience in the conduct of and support to epidemiological studies. Our activities include:
- Non-interventional studies on: burden of disease, safety, effectiveness, healthcare resource utilization, and others
- Primary data collection
- Feasibility
- Protocol development
- Investigators identification
- Data capture, transfer and storage
- Data and site monitoring
- Analysis and reporting
- Secondary use of electronic health record (EHR) databases, and access to a wide range of databases on demand
- Feasibility and fit-for-purpose assessment
- Protocol development
- Analysis and reporting
P95’s fundraising intiatives
/*! elementor - v3.11.5 - 14-03-2023 */
.elementor-widget-image{text-align:center}.elementor-widget-image a{display:inline-block}.elementor-widget-image a img[src$=".svg"]{width:48px}.elementor-widget-image img{vertical-align:middle;display:inline-block}
/*! elementor - v3.11.5 - 14-03-2023 */
.elementor-column .elementor-spacer-inner{height:var(--spacer-size)}.e-con{--container-widget-width:100%}.e-con-inner>.elementor-widget-spacer,.e-con>.elementor-widget-spacer{width:var(--container-widget-width,var(--spacer-size));--align-self:var(--container-widget-align-self,initial);--flex-shrink:0}.e-con-inner>.elementor-widget-spacer>.elementor-widget-container,.e-con-inner>.elementor-widget-spacer>.elementor-widget-container>.elementor-spacer,.e-con>.elementor-widget-spacer>.elementor-widget-container,.e-con>.elementor-widget-spacer>.elementor-widget-container>.elementor-spacer{height:100%}.e-con-inner>.elementor-widget-spacer>.elementor-widget-container>.elementor-spacer>.elementor-spacer-inner,.e-con>.elementor-widget-spacer>.elementor-widget-container>.elementor-spacer>.elementor-spacer-inner{height:var(--container-widget-height,var(--spacer-size))}
P95's Charity Donations
“From a deep respect for all human beings and our planet, we encourage and enable each other to thrive, learn and evolve” is part of P95’s purpose. As actions speak louder than words, from an internal fundraising initiative, P95 made multiple donations in 2023 that will help charities across the globe. The initiative, with a dual purpose of supporting our staff’s health and raise money for good causes, involved employees recording their physical activities in a company Strava club. For each hour of activity logged, the P95 management pledged to donate 2 euros to charity. This year, the money raised was donated to the following charities, chosen by P95 employees:
-
- Cool Earth: an organization that aims at helping rainforest communities, and funding projects that protect indigenous people impacted by the climate crisis. P95 believes the future of healthcare cannot be separated from the future of our planet.
More information on Cool Earth can be found here: https://www.coolearth.org/
- Cool Earth: an organization that aims at helping rainforest communities, and funding projects that protect indigenous people impacted by the climate crisis. P95 believes the future of healthcare cannot be separated from the future of our planet.
-
- Project for People: an organization that creates international projects in Italy, India, Brazil and Benin. P95’s donation helped the creation of the Nutritional Diet Project in India. This project aims at improving the living conditions of children in rural districts in West Bengal. With better tools, care and assistance this project combats malnutrition.
More information on Project for People can be found here: https://www.projectforpeople.org/
- Project for People: an organization that creates international projects in Italy, India, Brazil and Benin. P95’s donation helped the creation of the Nutritional Diet Project in India. This project aims at improving the living conditions of children in rural districts in West Bengal. With better tools, care and assistance this project combats malnutrition.
-
- Just Dig It: an organization that aims at cooling down the planet by restoring green spaces in Africa. So far, Just Dig It has restored around 300,000 hectares, and this amount keeps growing every day.
More information on Just Dig It: https://justdiggit.org/
- Just Dig It: an organization that aims at cooling down the planet by restoring green spaces in Africa. So far, Just Dig It has restored around 300,000 hectares, and this amount keeps growing every day.
-
- Lesoochranárske zoskupenie VLK: an organization that protects Slovak forests from deforestation. P95 supported their “Buy Your Own Tree” initiative that will help the organization acquire and protect more land.
More information on Lesoochranárske zoskupenie VLK can be found here: https://www.wolf.sk/en/en-home
- Lesoochranárske zoskupenie VLK: an organization that protects Slovak forests from deforestation. P95 supported their “Buy Your Own Tree” initiative that will help the organization acquire and protect more land.
Humanity and health are at the center of P95’s values. By helping charities and organizations, we hope to make the world a better place, not only for the future but also for the present.
P95 held its annual retreat in Mallorca
P95 held its annual retreat in Mallorca
At the beginning of October, we held our Annual Retreat in beautiful Mallorca. Around 100 employees were present! This was a great opportunity to network, meet our colleagues, discuss past, present and future of P95, acknowledge our diversity, and party together. What a wonderful couple of days!
A tour of our new P95 Latina office
A tour of our new P95 Latina office
We're excited to share a quick tour of our new P95 Latina office in Bogotá, Colombia, which opened in August 2022. The office provides a tailored space for our local team to meet, work together, or share a coffee. This is a new step toward strengthening our Latina branch office, a little over a year after its creation, and we hope our colleagues will make the most of it.
P95 presents 5 posters at the International Conference on Lyme Borreliosis 2022
P95 presents 5 posters at the International Conference on Lyme Borreliosis 2022
The P95 Lyme Team (Leah Burn, MPH, Jehidys Montiel Ramos, Aura Victoria Gutiérrez Rabá, Thao Mai Phuong Tran) presented 5 posters at the International Conference on Lyme Borreliosis (ICLB 2022) in Amsterdam, the Netherlands from Sept. 4th to 7th.
The posters were:
[P027] Incidence of Lyme Borreliosis in Europe from National Public Health Surveillance Systems (2005-2020)
[P028] Worldwide epidemiology of Lyme of disease outside the regions of North America, Europe, and China: A systematic review (2005-2020)
[P029] Incidence of Lyme Borreliosis in Europe, a systematic literature review (2005-2020)
[P030] Seroprevalence of Lyme Borreliosis in Europe: results from a systematic review (2005-2020)
[P047] Incidence of Lyme Disease in Asia from National Public Health Surveillance Systems (2011—2020)
P95 authors are on 6 total poster presentations at ICLB2022
P95 featured in the GIZ’s 2021 Integrated Company Report
P95 featured in the GIZ’s 2021 Integrated Company Report
The Deutsche Gesellschaft für Internationale Zusammenarbeit (GIZ) GmbH's 2021 Integrated Company Report highlights the international training program to enhance vaccine pharmacovigilance capacity in low and middle-income countries developed last year as a joint effort between P95 and GIZ. Through this initiative, our company contributed its knowledge and expertise on pharmacovigilance and vaccine safety and effectiveness studies, while GIZ provided support to roll out of the training through an international network, which included health agencies and experts from Ecuador, Ghana and Morocco.
You can find more on this initiative, featuring our team lead Zuleika Aponte (she/her/ella/elle), here: https://reporting.giz.de/2021/our-work-around-the-world/global-health/greater-vaccination-safety
DRIVE project comes to an end
DRIVE project comes to an end
After five years, the Development of Robust and Innovative Effectiveness (DRIVE) project has come to an end. Set up in July 2017, DRIVE’s main goal was to establish a sufficiently sized network for robust, high-quality, brand-specific IVE estimates for all vaccines used in the EU in each season. After the project's end, all the partners involved expect its legacy to continue through the development of a vaccine monitoring framework in the EU.
P95 was an active consortium partner in DRIVE, leading the work on the annual influenza vaccine effectiveness studies, performing the statistical analysis of the data and authoring the annual reports. In addition, the P95 IT-team developed a GDPR-compliant secure environment for repository of the sites' datasets and for data analysis. P95’s participation was led by Anke Stuurman.
DRIVE formed the basis for COVIDRIVE, a brand-specific COVID-19 vaccine effectiveness platform, co-founded and co-coordinated by P95.
P95 celebrates its 11th birthday
P95 Celebrates its 11th birthday
On June 16h, 2022, P95 turned 11 years old! To everyone who has allowed our company to achieve this milestone, thank you! We are so excited to celebrate one more year doing what believe in: finding, analysing and reporting epidemiological data to help health agencies, research organisations and pharma companies in their quest to improve people’s access to safe and effective vaccines. We are proud of the achievements that the past 11 years have brought and look forward to the future. Here’s to many more years working together, new wonderful projects and contributions to public health.